Weekly Endocrinology Research Analysis
This week’s endocrinology literature highlights rapid advances across metabolic mechanisms, reproductive protocols, and real-world therapeutics. A Cell mechanistic study identifies a druggable mitochondrial PEP shuttle (SLC25A35) that controls glycerolipid synthesis and improves steatosis in obese mice. A multicenter randomized trial shows a modified letrozole stimulation protocol yields comparable cumulative IVF outcomes and benefits a diminished-ovarian-reserve subgroup. Large real-world causa
Summary
This week’s endocrinology literature highlights rapid advances across metabolic mechanisms, reproductive protocols, and real-world therapeutics. A Cell mechanistic study identifies a druggable mitochondrial PEP shuttle (SLC25A35) that controls glycerolipid synthesis and improves steatosis in obese mice. A multicenter randomized trial shows a modified letrozole stimulation protocol yields comparable cumulative IVF outcomes and benefits a diminished-ovarian-reserve subgroup. Large real-world causal- inference analyses suggest GLP-1 receptor agonists may reduce major cardiorenal events in type 1 diabetes without increasing DKA or severe hypoglycemia.
Selected Articles
1. Mitochondrial control of glycerolipid synthesis by a PEP shuttle.
The study identifies SLC25A35 as a mitochondrial exporter of phosphoenolpyruvate (PEP) that enables glyceroneogenesis and glycerolipid synthesis; hepatic inhibition of SLC25A35 in obese mice reduced steatosis and improved glucose homeostasis, nominating a druggable mitochondrial node for metabolic disease.
Impact: Unveils a previously unrecognized mitochondrial metabolite shuttle with mechanistic depth and in vivo proof-of-concept, directly pointing to a novel therapeutic target for NAFLD and related metabolic disorders.
Clinical Implications: SLC25A35 inhibitors or modulators could limit hepatic glycerolipid synthesis and treat steatosis; validation in human hepatocytes and early-phase clinical testing is the next step for translation.
Key Findings
- SLC25A35 mediates pH gradient–dependent mitochondrial PEP export enabling glyceroneogenesis.
- Hepatic inhibition of SLC25A35 in obese mice alleviates steatosis and improves systemic glucose homeostasis.
2. Modified letrozole vs GnRH antagonist protocols in ovarian aging women for IVF: an open-label, multicenter, randomized controlled trial.
In 318 women with diminished ovarian reserve or advanced age, a modified letrozole protocol produced cumulative clinical pregnancy and live birth rates comparable to a GnRH antagonist protocol; notably, among diminished ovarian reserve patients undergoing dual fresh cleavage-stage transfers, the modified letrozole arm had higher clinical pregnancy rates.
Impact: Provides randomized, multicenter evidence informing stimulation-protocol selection in a difficult-to-treat IVF population and identifies a subgroup with clinically meaningful benefit.
Clinical Implications: Clinicians may consider a modified letrozole protocol as an alternative to GnRH antagonists for certain patients (notably diminished ovarian reserve with planned fresh dual transfers), while awaiting confirmatory trials powered for live birth outcomes.
Key Findings
- Comparable cumulative clinical pregnancy (32.1% vs 34.0%) and live birth rates (24.5% vs 22.6%) between mLP and GnRH antagonist.
- In diminished ovarian reserve patients with dual fresh cleavage-stage transfers, clinical pregnancy was higher with modified letrozole (65.8% vs 36.4%).
3. Glucagon-like peptide-1 receptor agonists for major cardiovascular and kidney outcomes in type 1 diabetes.
A nationwide target-trial emulation of 174,678 adults with type 1 diabetes found GLP-1RA initiation associated with lower 5-year risks of major adverse cardiovascular events and end-stage kidney disease without increased hospitalization for diabetic ketoacidosis or severe hypoglycemia, suggesting cardiorenal benefits in this population.
Impact: Largest real-world causal inference analysis to date suggesting cardiorenal benefit of GLP-1RAs in type 1 diabetes, which could expand therapeutic consideration beyond glycemic effects.
Clinical Implications: Consideration of GLP-1RAs as adjunct therapy for selected adults with type 1 diabetes at elevated cardiovascular or kidney risk may be warranted, with shared decision-making and careful monitoring until randomized trials provide confirmation.
Key Findings
- GLP-1RA initiation associated with lower 5-year MACE risk (4.3% vs 5.0%; HR 0.85) and reduced ESKD risk (1.6% vs 1.9%; HR 0.81).
- No increased hospitalization for diabetic ketoacidosis or severe hypoglycemia observed with GLP-1RA use.